News & Updates
Filter by Specialty:
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
31 May 2023
Vaccination protects the young against COVID-19
COVID-19 remains a global health concern, and children and adolescents are equally affected. In fact, COVID-19 hospitalization rates in children increased during the Omicron era. [MMWR 2022;71:271-278] In children aged 5–11 years who were hospitalized during the predominance of Omicron, nearly 90 percent were unvaccinated. [MMWR 2022;71:574-581]
Vaccination protects the young against COVID-19
31 May 2023
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
COVID-19 vaccine boosters provide protection against Omicron infection and related hospitalization among people with substance use disorder, researchers from the University of Hong Kong have reported.
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
29 May 2023
Vitamin D supplementation flops for TB prevention in children
A 3-year course of weekly oral vitamin D supplementation, while safe and effective at increasing serum 25(OH)D concentrations, does little to reduce the risk of contracting tuberculosis (TB) infection in children, as shown in the results of a phase III study.